Improving cancer immunotherapy by targeting tumor-induced immune suppression

Cancer and Metastasis Reviews

Volumn 30, Issue 1, 2011, Pages 125-140

  Stewart, Trina J ^a   Smyth, Mark J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Immune suppression; Immunotherapy; Inhibitory cytokines; MDSC; Tumor immunology

Indexed keywords

ADENOSINE; ARGINASE 1; CYCLOOXYGENASE 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIOXYGENASE; INDOLEAMINE 2,2 DIOXYGENASE; INTERLEUKIN 10; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; METABOLISM; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANIMALS; CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 79952281795     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-011-9280-5     Document Type: Article

References (157)

1. TJ Stewart KM Greeneltch ME Lutsiak SI Abrams 2007 Immunological responses can have both pro- and antitumour effects: implications for immunotherapy Expert Reviews in Molecular Medicine 9 4 1 20 10.1017/ S1462399407000233 17284328 (Pubitemid 46242913)
2. Hamai, A., Benlalam, H., Meslin, F., Hasmim, M., Carre, T., Akalay, I., et al. Immune surveillance of human cancer: If the cytotoxic t-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens, 75(1), 1-8, doi: 10.1111/j.1399-0039.2009.01401.x.
3. KL Knutson ML Disis 2005 Tumor antigen-specific T helper cells in cancer immunity and immunotherapy Cancer Immunology, Immunotherapy 54 8 721 728 16010587 1:CAS:528:DC%2BD2MXmtVajt78%3D (Pubitemid 40977140)
4. Bindea, G., Mlecnik, B., Fridman, W. H., Pages, F., & Galon, J. Natural immunity to cancer in humans. Current Opinion in Immunology, 22(2), 215-222, doi: 10.1016/j.coi.2010.02.006.
5. GP Dunn LJ Old RD Schreiber 2004 The immunobiology of cancer immunosurveillance and immunoediting Immunity 21 2 137 148 15308095 1:CAS:528:DC%2BD2cXnsVKltrY%3D (Pubitemid 39094044)
6. JB Swann MJ Smyth 2007 Immune surveillance of tumors Journal of Clinical Investigation 117 5 1137 1146 10.1172/JCI31405 17476343 1:CAS:528: DC%2BD2sXlt1Omtr0%3D (Pubitemid 46718398)
7. Ferrone, S., & Whiteside, T. L. (2007). Tumor microenvironment and immune escape. Surgical Oncology Clinics of North America, 16(4), 755-774, viii, doi: 10.1016/j.soc.2007.08.004. (Pubitemid 350101281)
8. TJ Stewart SI Abrams 2008 How tumours escape mass destruction Oncogene 27 45 5894 5903 10.1038/onc.2008.268 18836470 1:CAS:528:DC%2BD1cXhtF2msbbJ
9. Weiner, L. M., Surana, R., & Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews. Immunology, 10(5), 317-327, doi: 10.1038/nri2744.
10. M Kapp L Rasche H Einsele GU Grigoleit 2009 Cellular therapy to control tumor progression Current Opinion in Hematology 16 6 437 443 10.1097/MOH.0b013e32832f57d4 19587587
11. SA Rosenberg ME Dudley 2009 Adoptive cell therapy for the treatment of patients with metastatic melanoma Current Opinion in Immunology 21 2 233 240 10.1016/j.coi.2009.03.002 19304471 1:CAS:528:DC%2BD1MXlsVCgtb8%3D
12. Huye, L. E., & Dotti, G. Designing t cells for cancer immunotherapy. Discov Med, 9(47), 297-303.
13. Westwood, J. A., & Kershaw, M. H. Genetic redirection of t cells for cancer therapy. Journal of Leukocyte Biology, 87(5), 791-803, doi: 10.1189/jlb.1209824.
14. Spagnoli, G. C., Ebrahimi, M., Iezzi, G., Mengus, C., & Zajac, P. Contemporary immunotherapy of solid tumors: From tumor-associated antigens to combination treatments. Current Opinion in Drug Discovery & Development, 13(2), 184-192.
15. S Romagnani E Maggi F Liotta L Cosmi F Annunziato 2009 Properties and origin of human th17 cells Molecular Immunology 47 1 3 7 10.1016/j.molimm.2008. 12.019 19193443 1:CAS:528:DC%2BD1MXhtleksb3E
16. Mougiakakos, D., Choudhury, A., Lladser, A., Kiessling, R., & Johansson, C. C. Regulatory t cells in cancer. Advances in Cancer Research, 107, 57-117, doi: 10.1016/S0065-230X(10)07003-X.
17. Nishikawa, H., & Sakaguchi, S. Regulatory t cells in tumor immunity. International Journal of Cancer, 127(4), 759-767, doi: 10.1002/ijc.25429.
18. Teng, M. W., Ritchie, D. S., Neeson, P., & Smyth, M. J. Biology and clinical observations of regulatory t cells in cancer immunology. Current topics in Microbiology and Immunology, doi: 10.1007/82-2010-50.
19. P Serafini I Borrello V Bronte 2006 Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression Seminars in Cancer Biology 16 1 53 65 16168663 1:CAS:528:DC%2BD28XotVCmuw%3D%3D (Pubitemid 43139709)
20. P Allavena A Sica C Garlanda A Mantovani 2008 The yin-yang of tumor-associated macrophages in neoplastic progression and immune surveillance Immunological Reviews 222 155 161 10.1111/j.1600-065X.2008.00607.x 18364000 1:CAS:528:DC%2BD1cXlsFejtrc%3D (Pubitemid 351430369)
21. DI Gabrilovich S Nagaraj 2009 Myeloid-derived suppressor cells as regulators of the immune system Nature Reviews. Immunology 9 3 162 174 10.1038/nri2506 19197294 1:CAS:528:DC%2BD1MXhsFeqsbw%3D
22. I Marigo L Dolcetti P Serafini P Zanovello V Bronte 2008 Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells Immunological Reviews 222 162 179 10.1111/j.1600-065X.2008.00602.x 18364001 1:CAS:528:DC%2BD1cXlsFejt74%3D (Pubitemid 351430364)
23. B Almand JI Clark E Nikitina J van Beynen NR English SC Knight, et al. 2001 Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer Journal of Immunology 166 1 678 689 1:CAS:528:DC%2BD3MXis1elsw%3D%3D (Pubitemid 32038493)
24. CM Diaz-Montero ML Salem MI Nishimura E Garrett-Mayer DJ Cole AJ Montero 2009 Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy Cancer Immunology, Immunotherapy 58 1 49 59 10.1007/s00262-008- 0523-4 18446337 1:CAS:528:DC%2BD1cXht1yqs7bN
25. A Sica V Bronte 2007 Altered macrophage differentiation and immune dysfunction in tumor development Journal of Clinical Investigation 117 5 1155 1166 10.1172/JCI31422 17476345 1:CAS:528:DC%2BD2sXlt1Omtrs%3D (Pubitemid 46718400)
26. MR Young K Kolesiak MA Wright DI Gabrilovich 1999 Chemoattraction of femoral cd34+ progenitor cells by tumor-derived vascular endothelial cell growth factor Clinical & Experimental Metastasis 17 10 881 888 1:CAS:528:DC%2BD3cXos1Orsro%3D
27. AH Zea PC Rodriguez MB Atkins C Hernandez S Signoretti J Zabaleta, et al. 2005 Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion Cancer Research 65 8 3044 3048 10.1158/0008-5472.CAN-04-4505 15833831 1:CAS:528:DC%2BD2MXjt1yks7g%3D (Pubitemid 40524582)
28. P Filipazzi R Valenti V Huber L Pilla P Canese M Iero, et al. 2007 Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine Journal of Clinical Oncology 25 18 2546 2553 10.1200/JCO.2006.08.5829 17577033 1:CAS:528:DC%2BD2sXotV2mt7Y%3D (Pubitemid 47041228)
29. B Hoechst LA Ormandy M Ballmaier F Lehner C Kruger MP Manns, et al. 2008 A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces cd4(+)cd25(+)foxp3(+) T cells Gastroenterology 135 1 234 243 10.1053/j.gastro.2008.03.020 18485901 1:CAS:528:DC%2BD1cXps1Wltb0%3D (Pubitemid 351899008)
30. EA Danna P Sinha M Gilbert VK Clements BA Pulaski S Ostrand-Rosenberg 2004 Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease Cancer Research 64 6 2205 2211 15026364 1:CAS:528:DC%2BD2cXitFCgu7g%3D (Pubitemid 38339474)
31. P Serafini C De Santo I Marigo S Cingarlini L Dolcetti G Gallina, et al. 2004 Derangement of immune responses by myeloid suppressor cells Cancer Immunology, Immunotherapy 53 2 64 72 14593498 1:CAS:528:DC%2BD3sXpvVeksbY%3D (Pubitemid 38161211)
32. de Waal Malefyt, R., Yssel, H., & de Vries, J. E. (1993). Direct effects of il-10 on subsets of human cd4+ t cell clones and resting t cells. Specific inhibition of il-2 production and proliferation. Journal of Immunology, 150(11), 4754-4765. (Pubitemid 23150343)
33. F Koch U Stanzl P Jennewein K Janke C Heufler E Kampgen, et al. 1996 High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10 The Journal of Experimental Medicine 184 2 741 746 8760828 1:CAS:528:DyaK28XltVCrsbY%3D (Pubitemid 26324128)
34. KW Moore R de Waal Malefyt RL Coffman A O'Garra 2001 Interleukin-10 and the interleukin-10 receptor Annual Review of Immunology 19 683 765 10.1146/annurev.immunol.19.1.683 11244051 1:CAS:528:DC%2BD3MXivFKgu70%3D (Pubitemid 32368050)
35. V Bronte M Wang WW Overwijk DR Surman F Pericle SA Rosenberg, et al. 1998 Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells Journal of Immunology 161 10 5313 5320 1:CAS:528:DyaK1cXnsVOrtb0%3D (Pubitemid 28519091)
36. G Gallina L Dolcetti P Serafini C De Santo I Marigo MP Colombo, et al. 2006 Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells Journal of Clinical Investigation 116 10 2777 2790 17016559 1:CAS:528:DC%2BD28XhtVKgu7vF (Pubitemid 44511641)
37. AH Zea PC Rodriguez KS Culotta CP Hernandez J DeSalvo JB Ochoa, et al. 2004 l-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes Cellular Immunology 232 1-2 21 31 15922712 1:CAS:528:DC%2BD2MXls1Gmtbg%3D (Pubitemid 40732717)
38. C De Santo P Serafini I Marigo L Dolcetti M Bolla P Del Soldato, et al. 2005 Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination Proceedings of the National Academy of Sciences of the United States of America 102 11 4185 4190 15753302 (Pubitemid 40388577)
39. LA Pekarek BA Starr AY Toledano H Schreiber 1995 Inhibition of tumor growth by elimination of granulocytes The Journal of Experimental Medicine 181 1 435 440 7807024 1:CAS:528:DyaK2MXisl2rsLs%3D
40. TJ Stewart DJ Liewehr SM Steinberg KM Greeneltch SI Abrams 2009 Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells Journal of Immunology 183 1 117 128 10.4049/jimmunol.0804132 1:CAS:528:DC%2BD1MXnsVOrtLc%3D
41. TJ Stewart KM Greeneltch JE Reid DJ Liewehr SM Steinberg K Liu, et al. 2009 Interferon regulatory factor-8 modulates the development of tumour-induced CD11B+Gr-1+ myeloid cells Journal of Cellular and Molecular Medicine 13 9B 3939 3950 10.1111/j.1582-4934.2009.00685.x 20196788
42. M Kortylewski M Kujawski T Wang S Wei S Zhang S Pilon-Thomas, et al. 2005 Inhibiting stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity Natural Medicines 11 12 1314 1321 10.1038/nm1325 1:CAS:528:DC%2BD2MXht1yisr3I (Pubitemid 41752912)
43. Y Nefedova S Nagaraj A Rosenbauer C Muro-Cacho SM Sebti DI Gabrilovich 2005 Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway Cancer Research 65 20 9525 9535 16230418 1:CAS:528:DC%2BD2MXhtFWmu7rL (Pubitemid 41508023)
44. P Sinha VK Clements S Ostrand-Rosenberg 2005 Reduction of myeloid-derived suppressor cells and induction of m1 macrophages facilitate the rejection of established metastatic disease Journal of Immunology 174 2 636 645 1:CAS:528:DC%2BD2MXotFSg (Pubitemid 40094255)
45. S Kusmartsev F Cheng B Yu Y Nefedova E Sotomayor R Lush, et al. 2003 All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination Cancer Research 63 15 4441 4449 12907617 1:CAS:528:DC%2BD3sXmtFersr0%3D (Pubitemid 36951016)
46. MR Young Y Lozano J Ihm MA Wright MM Prechel 1996 Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells Cancer Letters 104 2 153 161 8665483 1:CAS:528:DyaK28XjtlSmu7Y%3D (Pubitemid 26181005)
47. MR Young MA Wright 1992 Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis Cancer Research 52 22 6335 6340 1423279 1:CAS:528:DyaK3sXlsVSm
48. N Mirza M Fishman I Fricke M Dunn AM Neuger TJ Frost, et al. 2006 All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients Cancer Research 66 18 9299 9307 10.1158/0008-5472. CAN-06-1690 16982775 1:CAS:528:DC%2BD28Xps1ahsrk%3D (Pubitemid 44521152)
49. Ko, J. S., Rayman, P., Ireland, J., Swaidani, S., Li, G., Bunting, K. D., et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Research, 70(9), 3526-3536, doi: 10.1158/0008-5472.CAN-09-3278.
50. HK Le L Graham E Cha JK Morales MH Manjili HD Bear 2009 Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice International Immunopharmacology 9 7-8 900 909 10.1016/j.intimp.2009.03.015 19336265 1:CAS:528:DC%2BD1MXms1Orsrk%3D
51. J Ozao-Choy G Ma J Kao GX Wang M Meseck M Sung, et al. 2009 The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies Cancer Research 69 6 2514 2522 10.1158/0008-5472.CAN-08-4709 19276342 1:CAS:528:DC%2BD1MXjtFyqurY%3D
52. E Suzuki V Kapoor AS Jassar LR Kaiser SM Albelda 2005 Gemcitabine selectively eliminates splenic Gr-1+/CD11b+myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clinical Cancer Research 11 18 6713 6721 16166452 1:CAS:528:DC%2BD2MXhtVShsb3O (Pubitemid 41339014)
53. Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced t cell-dependent antitumor immunity. Cancer Research, 70(8), 3052-3061, doi: 10.1158/0008-5472. CAN-09-3690.
54. JS Ko AH Zea BI Rini JL Ireland P Elson P Cohen, et al. 2009 Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Clinical Cancer Research 15 6 2148 2157 10.1158/1078-0432. CCR-08-1332 19276286 1:CAS:528:DC%2BD1MXjtF2rurY%3D
55. Fridlender, Z. G., Sun, J., Singhal, S., Kapoor, V., Cheng, G., Suzuki, E., et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Molecular Therapy, doi: 10.1038/mt.2010.159.
56. DI Godfrey KJ Hammond LD Poulton MJ Smyth AG Baxter 2000 NKT cells: facts, functions and fallacies Immunology Today 21 11 573 583 11094262 1:CAS:528:DC%2BD3cXotlCnsbs%3D
57. DI Godfrey S Stankovic AG Baxter 2010 Raising the NKT cell family Nature Immunology 11 3 197 206 10.1038/ni.1841 20139988 1:CAS:528:DC%2BC3cXhs1Onsbo%3D
58. MJ Smyth NY Crowe Y Hayakawa K Takeda H Yagita DI Godfrey 2002 NKT cells-conductors of tumor immunity? Current Opinion in Immunology 14 2 165 171 11869887 1:CAS:528:DC%2BD38XhsFCru7c%3D
59. MJ Smyth DI Godfrey 2000 NKT cells and tumor immunity-a double-edged sword Nature Immunology 1 6 459 460 10.1038/82698 11101862 1:CAS:528: DC%2BD3cXoslyrurw%3D
60. V Cerundolo JD Silk SH Masri M Salio 2009 Harnessing invariant NKT cells in vaccination strategies Nature Reviews. Immunology 9 1 28 38 10.1038/nri2451 19079136 1:CAS:528:DC%2BD1MXpt1Cr
61. Smyth, M. J., Crowe, N. Y., Pellicci, D. G., Kyparissoudis, K., Kelly, J. M., Takeda, K., et al. (2002). Sequential production of interferon-gamma by nk1.1(+) t cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide. Blood, 99(4), 1259-1266. (Pubitemid 34547079)
62. E Ambrosino M Terabe RC Halder J Peng S Takaku S Miyake, et al. 2007 Cross-regulation between type I and type II nkt cells in regulating tumor immunity: a new immunoregulatory axis Journal of Immunology 179 8 5126 5136 1:CAS:528:DC%2BD2sXhtFWitrvJ
63. AM Moodycliffe D Nghiem G Clydesdale SE Ullrich 2000 Immune suppression and skin cancer development: regulation by NKT cells Nature Immunology 1 6 521 525 10.1038/82782 11101875 1:CAS:528:DC%2BD3cXoslyru7s%3D
64. M Terabe C Khanna S Bose F Melchionda A Mendoza CL Mackall, et al. 2006 Cd1d-restricted natural killer t cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta Cancer Research 66 7 3869 3875 16585215 1:CAS:528:DC%2BD28XjtVOru7c%3D
65. M Terabe S Matsui N Noben-Trauth H Chen C Watson DD Donaldson, et al. 2000 NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway Nature Immunology 1 6 515 520 11101874 1:CAS:528: DC%2BD3cXoslyru7o%3D
66. M Terabe J Swann E Ambrosino P Sinha S Takaku Y Hayakawa, et al. 2005 A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance The Journal of Experimental Medicine 202 12 1627 1633 16365146 1:CAS:528:DC%2BD2MXhtlCjsrvF (Pubitemid 41815868)
67. JM Park M Terabe DD Donaldson G Forni JA Berzofsky 2008 Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation Cancer Immunology, Immunotherapy 57 6 907 912 10.1007/s00262-007-0414-0 18004566 1:CAS:528:DC%2BD1cXjvFKmtL0%3D
68. M Terabe S Matsui JM Park M Mamura N Noben-Trauth DD Donaldson, et al. 2003 Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted t cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence The Journal of Experimental Medicine 198 11 1741 1752 14657224 1:CAS:528:DC%2BD3sXps1egurY%3D (Pubitemid 37494166)
69. M Terabe JM Park JA Berzofsky 2004 Role of IL-13 in regulation of anti-tumor immunity and tumor growth Cancer Immunology, Immunotherapy 53 2 79 85 14610620 1:CAS:528:DC%2BD3sXpvVektr8%3D (Pubitemid 38161213)
70. G Parmiani L Rivoltini G Andreola M Carrabba 2000 Cytokines in cancer therapy Immunology Letters 74 1 41 44 10996626 1:CAS:528:DC%2BD3cXms1Srtro%3D
71. TJ Stewart MJ Smyth 2009 Chemokine-chemokine receptors in cancer immunotherapy Immunotherapy 1 1 109 127 10.2217/1750743X.1.1.109 20635978 1:CAS:528:DC%2BD1MXhtVygsrrE
72. L Gorelik RA Flavell 2002 Transforming growth factor-beta in T-cell biology Nature Reviews. Immunology 2 1 46 53 10.1038/nri704 11905837 1:CAS:528:DC%2BD38XhslyitL8%3D (Pubitemid 37328775)
73. JJ Letterio AB Roberts 1998 Regulation of immune responses by TGF-beta Annual Review of Immunology 16 137 161 10.1146/annurev.immunol.16.1.137 9597127 1:CAS:528:DyaK1cXislyhsrk%3D (Pubitemid 28183362)
74. MO Li RA Flavell 2008 TGF-beta: a master of all T cell trades Cell 134 3 392 404 10.1016/j.cell.2008.07.025 18692464 1:CAS:528:DC%2BD1cXhtVSis77N
75. TA Borkowski JJ Letterio AG Farr MC Udey 1996 A role for endogenous transforming growth factor beta 1 in langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal langerhans cells The Journal of Experimental Medicine 184 6 2417 2422 8976197 1:CAS:528:DyaK2sXjsFCr (Pubitemid 27023742)
76. F Geissmann P Revy A Regnault Y Lepelletier M Dy N Brousse, et al. 1999 TGF-beta 1 prevents the noncognate maturation of human dendritic langerhans cells Journal of Immunology 162 8 4567 4575 1:CAS:528:DyaK1MXisFOmtrs%3D (Pubitemid 29314856)
77. B Bierie HL Moses 2006 Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer Nature Reviews. Cancer 6 7 506 520 10.1038/nrc1926 16794634 1:CAS:528:DC%2BD28XmtFegsr4%3D (Pubitemid 43980540)
78. Takaku, S., Terabe, M., Ambrosino, E., Peng, J., Lonning, S., McPherson, J. M., et al. Blockade of tgf-beta enhances tumor vaccine efficacy mediated by cd8(+) t cells. International Journal of Cancer, 126(7), 1666-1674, doi: 10.1002/ijc.24961.
79. M Terabe E Ambrosino S Takaku JJ O'Konek D Venzon S Lonning, et al. 2009 Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody Clinical Cancer Research 15 21 6560 6569 10.1158/1078-0432.CCR-09-1066 19861451 1:CAS:528:DC%2BD1MXhtlCjsrbM
80. R Ueda M Fujita X Zhu K Sasaki ER Kastenhuber G Kohanbash, et al. 2009 Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines Clinical Cancer Research 15 21 6551 6559 10.1158/1078-0432.CCR-09-1067 19861464 1:CAS:528:DC%2BD1MXhtlCjsrnF
81. Nagaraj, N. S., & Datta, P. K. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opinion on Investigational Drugs, 19(1), 77-91, doi: 10.1517/13543780903382609.
82. M Uhl S Aulwurm J Wischhusen M Weiler JY Ma R Almirez, et al. 2004 SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo Cancer Research 64 21 7954 7961 10.1158/0008-5472.CAN-04-1013 15520202 1:CAS:528:DC%2BD2cXptFels78%3D (Pubitemid 39446929)
83. P Hau P Jachimczak U Bogdahn 2009 Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides Expert Review of Anticancer Therapy 9 11 1663 1674 10.1586/era.09.138 19895249 1:CAS:528:DC%2BD1MXhtl2rsbrL
84. P Hau P Jachimczak R Schlingensiepen F Schulmeyer T Jauch A Steinbrecher, et al. 2007 Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies Oligonucleotides 17 2 201 212 10.1089/oli.2006.0053 17638524 1:CAS:528:DC%2BD2sXnsl2nsro%3D (Pubitemid 47124417)
85. J Nemunaitis M Nemunaitis N Senzer P Snitz C Bedell P Kumar, et al. 2009 Phase II trial of Belagenpumatucel-l, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients Cancer Gene Therapy 16 8 620 624 10.1038/cgt.2009.15 19287371 1:CAS:528:DC%2BD1MXjtFCju7o%3D
86. AP Vicari G Trinchieri 2004 Interleukin-10 in viral diseases and cancer: exiting the labyrinth? Immunological Reviews 202 223 236 10.1111/j.0105-2896. 2004.00216.x 15546396 1:CAS:528:DC%2BD2MXhs1OhtA%3D%3D (Pubitemid 39576915)
87. Bagri, A., Kouros-Mehr, H., Leong, K. G., & Plowman, G. D. Use of anti-vegf adjuvant therapy in cancer: Challenges and rationale. Trends in Molecular Medicine, 16(3), 122-132, doi: 10.1016/j.molmed.2010.01.004.
88. B Johnson T Osada T Clay H Lyerly M Morse 2009 Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression Current Molecular Medicine 9 6 702 707 19689297 1:CAS:528:DC%2BD1MXhtVWkt7nI
89. DI Gabrilovich T Ishida S Nadaf JE Ohm DP Carbone 1999 Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function Clinical Cancer Research 5 10 2963 2970 10537366 1:CAS:528:DyaK1MXntlGlu7w%3D (Pubitemid 29493976)
90. C Alfaro N Suarez A Gonzalez S Solano L Erro J Dubrot, et al. 2009 Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes British Journal of Cancer 100 7 1111 1119 10.1038/sj.bjc.6604965 19277038 1:CAS:528:DC%2BD1MXktVGktro%3D
91. B Li AS Lalani TC Harding B Luan K Koprivnikar G Huan Tu, et al. 2006 Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy Clinical Cancer Research 12 22 6808 6816 10.1158/1078-0432.CCR-06-1558 17121902 1:CAS:528:DC%2BD28Xht1elsLzE (Pubitemid 44876851)
92. T Osada G Chong R Tansik T Hong N Spector R Kumar, et al. 2008 The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients Cancer Immunology, Immunotherapy 57 8 1115 1124 10.1007/s00262-007- 0441-x 18193223 1:CAS:528:DC%2BD1cXmt1OisLY%3D
93. BI Rini V Weinberg L Fong S Conry RM Hershberg EJ Small 2006 Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy Cancer 107 1 67 74 10.1002/cncr.21956 16736512 1:CAS:528:DC%2BD28XntVymu70%3D (Pubitemid 43939032)
94. I Conti BJ Rollins 2004 CCL2 (monocyte chemoattractant protein-1) and cancer Seminars in Cancer Biology 14 3 149 154 15246049 1:CAS:528: DC%2BD2cXjvVemsb4%3D (Pubitemid 38586739)
95. H Hasegawa A Inoue M Muraoka J Yamanouchi T Miyazaki M Yasukawa 2007 Therapy for pneumonitis and sialadenitis by accumulation of CCR2-expressing CD4+CD25+ regulatory T cells in MRL/lpr mice Arthritis Research & Therapy 9 1 R15 10.1186/ar2122 (Pubitemid 46336460)
96. K Hu J Xiong K Ji H Sun J Wang H Liu 2007 Recombined CC chemokine ligand 2 into B16 cells induces production of th2-dominant [correction of dominanted] cytokines and inhibits melanoma metastasis Immunology Letters 113 1 19 28 10.1016/j.imlet.2007.07.004 17868906 1:CAS:528:DC%2BD2sXhtFSnu73L (Pubitemid 47464614)
97. L Peng S Shu JC Krauss 1997 Monocyte chemoattractant protein inhibits the generation of tumor-reactive t cells Cancer Research 57 21 4849 4854 9354448 1:CAS:528:DyaK2sXnt12nsr8%3D (Pubitemid 27468993)
98. T Ueno M Toi H Saji M Muta H Bando K Kuroi, et al. 2000 Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer Clinical Cancer Research 6 8 3282 3289 10955814 1:CAS:528:DC%2BD3cXmsVOmt7c%3D (Pubitemid 30637758)
99. JT Jordan W Sun SF Hussain G DeAngulo SS Prabhu AB Heimberger 2008 Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy Cancer Immunology, Immunotherapy 57 1 123 131 10.1007/s00262-007-0336-x 17522861 1:CAS:528:DC%2BD2sXht1aqs77P (Pubitemid 350043644)
100. JW Pollard 2004 Tumour-educated macrophages promote tumour progression and metastasis Nature Reviews. Cancer 4 1 71 78 10.1038/nrc1256 nrc1256 14708027 1:CAS:528:DC%2BD2cXos12qtA%3D%3D (Pubitemid 38082155)
101. RD Loberg C Ying M Craig LL Day E Sargent C Neeley, et al. 2007 Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo Cancer Research 67 19 9417 9424 17909051 1:CAS:528:DC%2BD2sXhtFSnurrE (Pubitemid 47535932)
102. RD Loberg C Ying M Craig L Yan LA Snyder KJ Pienta 2007 CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration Neoplasia 9 7 556 562 17710158 1:CAS:528: DC%2BD2sXptlKrtbY%3D (Pubitemid 47121829)
103. Fridlender, Z. G., Buchlis, G., Kapoor, V., Cheng, G., Sun, J., Singhal, S., et al. Ccl2 blockade augments cancer immunotherapy. Cancer Research, 70(1), 109-118, doi: 10.1158/0008-5472.CAN-09-2326.
104. JH Li D Rosen P Sondel G Berke 2002 Immune privilege and FasL: two ways to inactivate effector cytotoxic t lymphocytes by FasL-expressing cells Immunology 105 3 267 277 11918688 1:CAS:528:DC%2BD38Xit1GrsLo%3D (Pubitemid 34304403)
105. RH Schwartz 2003 T cell anergy Annual Review of Immunology 21 305 334 10.1146/annurev.immunol.21.120601.141110 12471050 1:CAS:528:DC%2BD3sXjtF2isrs%3D (Pubitemid 37174534)
106. JW Greiner H Zeytin MR Anver J Schlom 2002 Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity Cancer Research 62 23 6944 6951 12460911 1:CAS:528:DC%2BD38XpsVahsLk%3D (Pubitemid 35424085)
107. JP Eder PW Kantoff K Roper GX Xu GJ Bubley J Boyden, et al. 2000 A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer Clinical Cancer Research 6 5 1632 1638 10815880 1:CAS:528:DC%2BD3cXktVWju7c%3D (Pubitemid 30305054)
108. JL Marshall JL Gulley PM Arlen PK Beetham KY Tsang R Slack, et al. 2005 Phase i study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte- macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas Journal of Clinical Oncology 23 4 720 731 10.1200/JCO.2005.10.206 15613691 1:CAS:528:DC%2BD2MXitVKisbY%3D (Pubitemid 46224171)
109. AB Frey N Monu 2008 Signaling defects in anti-tumor T cells Immunological Reviews 222 192 205 10.1111/j.1600-065X.2008.00606.x 18364003 1:CAS:528:DC%2BD1cXlsFejt7w%3D (Pubitemid 351430368)
110. Whiteside, T. L. Immune responses to malignancies. Journal of Allergy and Clinical Immunology, 125(2 Suppl 2), S272-S283, doi: 10.1016/j.jaci.2009.09. 045.
111. JG Egen MS Kuhns JP Allison 2002 CTLA-4: new insights into its biological function and use in tumor immunotherapy Nature Immunology 3 7 611 618 12087419 1:CAS:528:DC%2BD38Xksl2mtbs%3D (Pubitemid 34752469)
112. A Boasso JP Herbeuval AW Hardy C Winkler GM Shearer 2005 Regulation of indoleamine 2, 3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells Blood 105 4 1574 1581 10.1182/blood-2004-06-2089 15466932 1:CAS:528:DC%2BD2MXhsVChtbs%3D (Pubitemid 40223677)
113. Mangsbo, S. M., Sandin, L. C., Anger, K., Korman, A. J., Loskog, A., & Totterman, T. H. Enhanced tumor eradication by combining ctla-4 or pd-1 blockade with cpg therapy. Journal of Immunotherapy, 33(3), 225-235, doi: 10.1097/CJI.0b013e3181c01fcb.
114. Takeda, K., Kojima, Y., Uno, T., Hayakawa, Y., Teng, M. W., Yoshizawa, H., et al. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. Journal of Immunology, 184(10), 5493-5501, doi: 10.4049/jimmunol.0903033.
115. AA Sarnaik JS Weber 2009 Recent advances using anti-CTLA-4 for the treatment of melanoma Cancer Journal 15 3 169 173 10.1097/PPO.0b013e3181a7450f 1:CAS:528:DC%2BD1MXot12rsL8%3D
116. Agarwala, S. S. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: Cytotoxic t-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Research, 20(1), 1-10, doi: 10.1097/CMR. 0b013e328333bbc8.
117. Page, D. B., Yuan, J., & Wolchok, J. D. Targeting cytotoxic t-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy, 2(3), 367-379, doi: 10.2217/imt.10.21.
118. JS Weber 2006 The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies Melanoma Research 16 5 379 383 10.1097/01.cmr.0000232292.06785.a3 17013086 1:CAS:528:DC%2BD28XhtVWntr7O (Pubitemid 44511217)
119. H Dong SE Strome DR Salomao H Tamura F Hirano DB Flies, et al. 2002 Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Natural Medicines 8 8 793 800 1:CAS:528:DC%2BD38Xls12msLo%3D
120. J Fourcade P Kudela Z Sun H Shen SR Land D Lenzner, et al. 2009 PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients Journal of Immunology 182 9 5240 5249 10.4049/jimmunol.0803245 1:CAS:528:DC%2BD1MXkslKju7c%3D
121. Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., et al. Tumor-infiltrating ny-eso-1-specific cd8+ t cells are negatively regulated by lag-3 and pd-1 in human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(17), 7875-7880, doi: 10.1073/pnas.1003345107.
122. Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., et al. Upregulation of tim-3 and pd-1 expression is associated with tumor antigen-specific cd8+ t cell dysfunction in melanoma patients. Journal of Experimental Medicine, doi: 10.1084/jem.20100637.
123. M Ichikawa L Chen 2005 Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms Frontiers in Bioscience 10 2856 2860 15970540 1:CAS:528: DC%2BD2MXntFGisbg%3D (Pubitemid 40910526)
124. W Wang R Lau D Yu W Zhu A Korman J Weber 2009 PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(hi) regulatory t cells International Immunology 21 9 1065 1077 10.1093/intimm/dxp072 19651643 1:CAS:528:DC%2BD1MXhtVKntbvK
125. TJ Curiel S Wei H Dong X Alvarez P Cheng P Mottram, et al. 2003 Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity Natural Medicines 9 5 562 567 10.1038/nm863 1:CAS:528:DC%2BD3sXjtlamtLc%3D (Pubitemid 36597102)
126. Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., et al. Phase i study of single-agent anti-programmed death-1 (mdx-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology, 28(19), 3167-3175, doi: 10.1200/JCO.2009.26.7609.
127. P Li YL Yin D Li SW Kim G Wu 2007 Amino acids and immune function The British Journal of Nutrition 98 2 237 252 10.1017/S000711450769936X 17403271 1:CAS:528:DC%2BD2sXpsFentrg%3D (Pubitemid 47091364)
128. V Bronte P Zanovello 2005 Regulation of immune responses by l-arginine metabolism Nature Reviews. Immunology 5 8 641 654 16056256 1:CAS:528: DC%2BD2MXmvVClsLc%3D (Pubitemid 41113195)
129. S Mocellin V Bronte D Nitti 2007 Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities Medicinal Research Reviews 27 3 317 352 10.1002/med.20092 16991100 1:CAS:528:DC%2BD2sXmtVGrt7g%3D (Pubitemid 46668937)
130. PC Rodriguez DG Quiceno J Zabaleta B Ortiz AH Zea MB Piazuelo, et al. 2004 Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses Cancer Research 64 16 5839 5849 15313928 1:CAS:528:DC%2BD2cXmslaks70%3D (Pubitemid 39095585)
131. V Bronte T Kasic G Gri K Gallana G Borsellino I Marigo, et al. 2005 Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers The Journal of Experimental Medicine 201 8 1257 1268 15824085 1:CAS:528:DC%2BD2MXjs1Citb4%3D (Pubitemid 40629069)
132. Stagg, J., & Smyth, M. J. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene, doi: 10.1038/onc.2010.292.
133. Mandapathil, M., Hilldorfer, B., Szczepanski, M. J., Czystowska, M., Szajnik, M., Ren, J., et al. Generation and accumulation of immunosuppressive adenosine by human cd4+cd25highfoxp3+ regulatory t cells. Journal of Biological Chemistry, 285(10), 7176-7186, doi: 10.1074/jbc.M109.047423.
134. Jin, D., Fan, J., Wang, L., Thompson, L. F., Liu, A., Daniel, B. J., et al. Cd73 on tumor cells impairs antitumor t-cell responses: A novel mechanism of tumor-induced immune suppression. Cancer Research, 70(6), 2245-2255, doi: 10.1158/0008-5472.CAN-09-3109.
135. M Takedachi D Qu Y Ebisuno H Oohara ML Joachims ST McGee, et al. 2008 CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes Journal of Immunology 180 9 6288 6296 1:CAS:528:DC%2BD1cXkvVCjt70%3D
136. Stagg, J., Divisekera, U., McLaughlin, N., Sharkey, J., Pommey, S., Denoyer, D., et al. Anti-cd73 antibody therapy inhibits breast tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 107(4), 1547-1552, doi: 10.1073/pnas.0908801107.
137. C Uyttenhove L Pilotte I Theate V Stroobant D Colau N Parmentier, et al. 2003 Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase Natural Medicines 9 10 1269 1274 10.1038/nm934 nm934 1:CAS:528:DC%2BD3sXns1Clu7c%3D (Pubitemid 37279849)
138. X Liu RC Newton SM Friedman PA Scherle 2009 Indoleamine 2, 3-dioxygenase, an emerging target for anti-cancer therapy Current Cancer Drug Targets 9 8 938 952 20025603 1:CAS:528:DC%2BC3cXhslKnsLk%3D
139. S Lob A Konigsrainer HG Rammensee G Opelz P Terness 2009 Inhibitors of indoleamine-2, 3-dioxygenase for cancer therapy: can we see the wood for the trees? Nature Reviews. Cancer 9 6 445 452 10.1038/nrc2639 19461669
140. DH Munn M Zhou JT Attwood I Bondarev SJ Conway B Marshall, et al. 1998 Prevention of allogeneic fetal rejection by tryptophan catabolism Science 281 5380 1191 1193 9712583 1:CAS:528:DyaK1cXls1Cqu7c%3D (Pubitemid 28406294)
141. U Grohmann C Orabona F Fallarino C Vacca F Calcinaro A Falorni, et al. 2002 CTLA-4-Ig regulates tryptophan catabolism in vivo Nature Immunology 3 11 1097 1101 10.1038/ni846 ni846 12368911 1:CAS:528:DC%2BD38Xot1Chs7Y%3D (Pubitemid 35363664)
142. DH Munn MD Sharma D Hou B Baban JR Lee SJ Antonia, et al. 2004 Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes Journal of Clinical Investigation 114 2 280 290 10.1172/JCI21583 15254595 1:CAS:528:DC%2BD2cXlvFWmsbg%3D (Pubitemid 39071633)
143. DH Munn AL Mellor 2007 Indoleamine 2, 3-dioxygenase and tumor-induced tolerance Journal of Clinical Investigation 117 5 1147 1154 10.1172/JCI31178 17476344 1:CAS:528:DC%2BD2sXlt1Omtro%3D (Pubitemid 46718399)
144. AJ Muller GC Prendergast 2007 Indoleamine 2, 3-dioxygenase in immune suppression and cancer Current Cancer Drug Targets 7 1 31 40 17305476 1:CAS:528:DC%2BD2sXitVOgtr4%3D (Pubitemid 46345506)
145. AJ Muller JB DuHadaway PS Donover E Sutanto-Ward GC Prendergast 2005 Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy Natural Medicines 11 3 312 319 10.1038/nm1196 1:CAS:528:DC%2BD2MXhvVSru7c%3D (Pubitemid 40460560)
146. MT Wang KV Honn D Nie 2007 Cyclooxygenases, prostanoids, and tumor progression Cancer and Metastasis Reviews 26 3-4 525 534 10.1007/s10555-007- 9096-5 17763971 1:CAS:528:DC%2BD2sXht1yktLbP (Pubitemid 350115125)
147. G Gasparini R Longo R Sarmiento A Morabito 2003 Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? The Lancet Oncology 4 10 605 615 14554238 1:CAS:528:DC%2BD3sXnvVKksbo%3D (Pubitemid 37258402)
148. FH Sarkar S Adsule Y Li S Padhye 2007 Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy Mini Rev Med Chem 7 6 599 608 17584158 1:CAS:528:DC%2BD2sXlvFGmtr8%3D (Pubitemid 47099180)
149. A Greenhough HJ Smartt AE Moore HR Roberts AC Williams C Paraskeva, et al. 2009 The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment Carcinogenesis 30 3 377 386 10.1093/carcin/bgp014 19136477 1:CAS:528:DC%2BD1MXivFSiuro%3D
150. SG Harris J Padilla L Koumas D Ray RP Phipps 2002 Prostaglandins as modulators of immunity Trends in Immunology 23 3 144 150 11864843 1:CAS:528:DC%2BD38XhsFaht7w%3D (Pubitemid 34178297)
151. BA Pockaj GD Basu LB Pathangey RJ Gray JL Hernandez SJ Gendler, et al. 2004 Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer Annals of Surgical Oncology 11 3 328 339 14993030 (Pubitemid 40486775)
152. S Sharma SC Yang L Zhu K Reckamp B Gardner F Baratelli, et al. 2005 Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer Cancer Research 65 12 5211 5220 10.1158/0008-5472.CAN-05-0141 15958566 1:CAS:528:DC%2BD2MXltFemurc%3D (Pubitemid 40827331)
153. M Stolina S Sharma Y Lin M Dohadwala B Gardner J Luo, et al. 2000 Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis Journal of Immunology 164 1 361 370 1:CAS:528:DC%2BD3cXisFSr (Pubitemid 30013010)
154. GD Basu TL Tinder JM Bradley T Tu CL Hattrup BA Pockaj, et al. 2006 Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO Journal of Immunology 177 4 2391 2402 1:CAS:528:DC%2BD28Xns1Khurc%3D (Pubitemid 44201000)
155. Zeytin, H. E., Patel, A. C., Rogers, C. J., Canter, D., Hursting, S. D., Schlom, J., et al. (2004). Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in cea.Tg/min mice. Cancer Research, 64(10), 3668-3678, doi: 10.1158/0008-5472.CAN-03-3878. (Pubitemid 38657947)
156. I Csiki JD Morrow A Sandler Y Shyr J Oates MK Williams, et al. 2005 Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase ii trial of celecoxib and docetaxel Clinical Cancer Research 11 18 6634 6640 10.1158/1078-0432.CCR-05-0436 16166442 1:CAS:528:DC%2BD2MXhtVShsbzO (Pubitemid 41339004)
157. V Ferrari F Valcamonico V Amoroso E Simoncini L Vassalli P Marpicati, et al. 2006 Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase ii trial Cancer Chemotherapy and Pharmacology 57 2 185 190 10.1007/s00280-005-0028-1 16151811 1:CAS:528:DC%2BD2MXhtlSjtb3E (Pubitemid 41779837)